Accueil   Diary - News   All news GeNeuro’s ANGEL-MS Phase 2b study confirms and extends the neuroprotective effects of temelimab in MS

GeNeuro’s ANGEL-MS Phase 2b study confirms and extends the neuroprotective effects of temelimab in MS

 

Data Supports Temelimab’s Potential to Treat Disease Progression in MS

 

  •  Long-term neuroprotective effects confirmed in patients treated up to two years
  • Sustained benefits on cortical and thalamic atrophy and myelin integrity
  • Encouraging, dose-dependent effects seen on clinical measures of disease progression
  • Excellent tolerability continued to be observed, with no dose-limiting safety signals
  • GeNeuro will hold a conference call and webcast today Tuesday, March 12 at 2:30 pm CET / 9:30 am EDT, to share results

 

Geneva, Switzerland, 12 March 2019 – 07:00am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), type-1 diabetes (T1D) and amyotrophic lateral sclerosis (ALS), today announced positive results from the ANGEL-MS study of its lead product, temelimab in MS. Temelimab is a humanized, monoclonal antibody designed to neutralize pHERV-W, a pathogenic protein thought to be a causal factor in the development of multiple sclerosis.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree